Autoimmune diseases, where the body’s immune system attacks healthy cells, affect at least 23.5 people million in the U.S., according to the National Institutes of Health. (Though the Autoimmune Related Diseases Association estimates that number is closer to 50 million.)
“It’s getting worse and it is going up,” Harvard Medical School immunologist, pathologist and molecular microbiologist Dr. Noel Rose told today.
ImmuPharma PLC (LON:IMM) is headquartered in London and has its research operations in France (ImmuPharma (France) SA) and Switzerland (ImmuPharma AG). ImmuPharma is dedicated to the development of innovative drugs to treat serious medical conditions, characterised by High unmet medical need,Low marketing costs and Relatively low development costs